Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: John F. Dowd who wrote (6204)	11/4/1998 5:42:00 PM
From: Anthony Wong	Respond to of 9523

John, one or more of the following may have contributed to today's weakness: 1) The PFE/Hoechst news (which is good news to me), excerpt from Bloomberg article: news.com Shares of Germany's Hoechst rose 1.94 deutsche marks to 72.35 marks. Pfizer, which will now have to share the market with Hoechst's drug unit Hoechst Marion Roussel, fell 3 5/16 to 105 15/16. San Carlos, California-based Inhale rose 1 7/8 to 30 7/8. Inhaled insulin could generate as much as $1 billion in annual sales, said Caroline Copithorne, an analyst at Prudential Securities. ''It's going to expand insulin into a much larger market because of the higher price and the conversion of some patients, who are now reluctant to use injections, to inhaled insulin,'' she said. Until the Frankfurt factory is complete, Hoechst will provide the bulk insulin to Inhale for conversion into powered form. The Hoechst insulin will be used for final clinical trials, slated to begin in the first half of 1999, and initial sales of the product, the companies said. The addition of Hoechst's insulin production and its commitment to the new manufacturing site was critical for New York-based Pfizer and Inhale Therapeutics, since neither has much experience in the tricky process of making insulin and the inhaled, powder formulation is requires massive amounts of bulk insulin. Now, it's clear there will be a large enough insulin supply, and a strong international sales staff, to support a very successful product, Copithorne said. 3) Dura Pharmaceutical has some bad news from the FDA about their inhale technology (re. their inhaled asthma drug) and is down big today. 2) Henry Niman's post at the MTC board said that Merck had filed for Vioxx approval at FDA To: jopawa (445 ) From: Henry Niman Wednesday, Nov 4 1998 11:44AM ET Reply #446 of 465 Bear Stearns has a rumor that MRK has already filed a Vioxx application, but the report came out earlier. Details in New Therapeutics section of biocognizance.com 3) PFE has reached a Peabody peak of $110 today

To: John F. Dowd who wrote (6204)	11/4/1998 6:30:00 PM
From: BigKNY3	Read Replies (1) \| Respond to of 9523

John, I believe today's action reflects profit-taking from the recent run-up and anticipation of Friday's R&D meeting: PFE - PFIZER INC Last Price: 106 at 17:21 EST Change: Down 3 (-2.75%) High: 110 at 10:01 EST Low: 105 15/16 at 16:42 EST Open: 109 3/4 Previous Close: 109 on 11/3 Volume: 4,040,500 30-Day Avg. Volume: 4,165,000 Shares Outstanding: 1,306,595,000 52-Week High: 121 3/4 52-Week Low: 66.31 Beta: 1.07 Yield: 0.70% P/E Ratio: 42.57 EPS: 2.49 Today's downward trend matches Mr. P's 110 prediction made last Sunday. Pretty amazing!!! Peabody Short-Term PForecast (11/01/98): PFE: 107.31, DJ: 8592: This week's PFE's trend will reflect market momentum, profit-taking from the latest strong gain, Viagra media and, most important, the response to this Friday's annual PFE R&D meeting. Gut feel: Expect a bounce down from the 110 level. Long-term... still very bullish on PFE, however, the short-term could be choppy to below 103...again. Have PFun! BigKNY3